<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7076512/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Examples of approved nanoplatforms for drug delivery by the FDA, EMA and other organizations (updated table, after Singh et al. [ 
   <a rid="B185-pharmaceutics-12-00171" ref-type="bibr">185</a>]). 
  </p>
 </caption>
 <thead>
  <tr>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-0-.">Name</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-1-.">Company/Approval Year/Country/Organization</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-2-.">Nanoplatform. Benefits</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-3-.">Virus</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-4-.">Route of Administration</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-5-.">REF</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epaxal 
    <sup>®</sup>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crucell (former Berna Biotech Ltd.); 
    <br/>1994 Switzerland 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes (around 150 nm 
    <i>spherical liposomal vesicles</i>)—intrinsic adjuvant properties; reduced toxicity and superior tolerability; 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HAV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular vaccine</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B186-pharmaceutics-12-00171" ref-type="bibr">186</a>, 
    <a rid="B187-pharmaceutics-12-00171" ref-type="bibr">187</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflexal 
    <sup>®</sup> V 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crucell (former Berna Biotech Ltd.); 
    <br/>1997 Switzerland 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes (around 150 nm 
    <i>spherical liposomal vesicles</i>)—biodegradable and biocompatible adjuvant systems; unwanted side effects; superior immune response; 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular vaccine</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B187-pharmaceutics-12-00171" ref-type="bibr">187</a>, 
    <a rid="B188-pharmaceutics-12-00171" ref-type="bibr">188</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PegIntron 
    <sup>®</sup>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schering Corporation, 2001, U.S., FDA</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-interferon alfa-2b (polymeric NPs) —31.000 Daltons molecules; superior protein stability;</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B189-pharmaceutics-12-00171" ref-type="bibr">189</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pegasys 
    <sup>®</sup>
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genentech, 2002, U.S. FDA</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-interferon alfa-2a (polymeric NPs)—31.000 Daltons molecules; superior protein stability;</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV, HCV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B190-pharmaceutics-12-00171" ref-type="bibr">190</a>, 
    <a rid="B191-pharmaceutics-12-00171" ref-type="bibr">191</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influvac 
    <sup>®</sup> Plus 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BGP Pharma ULC, 
    <br/>2005, Canada 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosome vaccine</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular 
    <br/>vaccine 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B192-pharmaceutics-12-00171" ref-type="bibr">192</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VivaGel 
    <sup>®</sup> BV 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starpharma, Australia; 
    <br/>Mundipharma, Europe, 2019 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendrimer (astodrimer sodium—SPL7013) incorporated in a water-based vaginal gel, acting as a targeting antiviral biofilm.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV, HSV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topically Applied (Vaginal gel)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B193-pharmaceutics-12-00171" ref-type="bibr">193</a>] 
   </td>
  </tr>
 </tbody>
</table>
